Share

Biotron Limited (BIT) was established to develop research projects on the basis of intellectual property (IP) developed at the Australian National University's John Curtin School of Medical Research (JCSMR). The company’s core focus is on the licensing of compounds arising from these research projects to third parties, such as pharmaceutical companies, for eventual commercialisation. Key projects under development include a cancer diagnostic test and anti-viral agents for use in the treatment of HIV. The company was incorporated in February 1999 to fund, manage and commercialize biomedical projects resulting from research in a number of programs at the John Curtin School of Medical Research (JCSMR) within the Australian National University (ANU). The company's head office is located in Sydney, while its operations are located in research facilities in the Innovations Building at the ANU, Canberra as well as St Vincent's Hospital, Sydney. The company listed in January 2001.

Biotron Limited (BIT) is in a unique position to capitalise on medical research carried out at the Australian National University. BIT's products under development include a potential HIV treatment and a cancer diagnostic test. In addition, Biotron is targeting major pharmaceutical companies for the purposes of establishing licencing agreement. Technically, BIT is indirectly competing with other HIV-AIDS research/therapeutics companies with its Virion project, and other early cancer detection diagnostic manufacturers with its C-1 test.

Biotron (BIT) Products and Services

Conduct clinical trials

Research and commercialisation of a number of anti-viral (HCV and HIV) drugs

My Share Trading

Disclaimer: This site may include market analysis and other recommendations. All ideas, opinions, recommendations and/or forecasts, expressed or implied herein, are for informational and educational purposes only and should not be construed as financial product advice or an inducement or instruction to invest, trade, and/or speculate in the markets. Any action or refraining from action; investments, trades, and/or speculations made in light of the ideas, opinions, and/or forecasts, expressed or implied herein, are committed at your own risk an consequence, financial or otherwise.